Abstract
BackgroundAnti-cytosolic 5’-nucleotidase 1A (anti-cN1A) antibodies have recently been proposed as a biomarker for inclusion body myositis (IBM). With high specificity (87-100%), they can help differentiate IBM from other myositis.[1,2] Besides...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
